JP2017517520A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517520A5
JP2017517520A5 JP2016569847A JP2016569847A JP2017517520A5 JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5 JP 2016569847 A JP2016569847 A JP 2016569847A JP 2016569847 A JP2016569847 A JP 2016569847A JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
patient
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016569847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032351 external-priority patent/WO2015183776A1/en
Publication of JP2017517520A publication Critical patent/JP2017517520A/ja
Publication of JP2017517520A5 publication Critical patent/JP2017517520A5/ja
Pending legal-status Critical Current

Links

JP2016569847A 2014-05-29 2015-05-26 Ｗｅｅ１阻害剤を用いた癌を処置する方法 Pending JP2017517520A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004298P 2014-05-29 2014-05-29
US62/004,298 2014-05-29
PCT/US2015/032351 WO2015183776A1 (en) 2014-05-29 2015-05-26 Methods for treating cancer with a wee1 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019232432A Division JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Publications (2)

Publication Number Publication Date
JP2017517520A JP2017517520A (ja) 2017-06-29
JP2017517520A5 true JP2017517520A5 (2) 2018-06-28

Family

ID=54699632

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569847A Pending JP2017517520A (ja) 2014-05-29 2015-05-26 Ｗｅｅ１阻害剤を用いた癌を処置する方法
JP2019232432A Pending JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019232432A Pending JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Country Status (4)

Country Link
US (3) US20170095479A1 (2)
EP (1) EP3148544A4 (2)
JP (2) JP2017517520A (2)
WO (1) WO2015183776A1 (2)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183776A1 (en) * 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
TWI844602B (zh) 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
AU2020407070A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
JP2023521802A (ja) * 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
IL298549A (en) * 2020-06-24 2023-01-01 Pmv Pharmaceuticals Inc A companion diagnostic tool for compounds reactivating mutant p53
CN119241504A (zh) 2021-08-26 2025-01-03 沃拉斯查疗法公司 Kif18a的螺吲哚啉抑制剂
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608940T3 (es) * 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
US20120157342A1 (en) * 2009-09-02 2012-06-21 Shinji Mizuarai Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
US9506926B2 (en) * 2011-02-18 2016-11-29 The Regents Of The University Of California Molecular predictors of therapeutic response to specific anti-cancer agents
EP2755482B1 (en) * 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
WO2015183776A1 (en) * 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor

Similar Documents

Publication Publication Date Title
JP2017517520A5 (2)
JP2021521194A5 (2)
JP2016525097A5 (2)
JP2015533176A5 (2)
JP2016533366A5 (2)
MX2021001583A (es) Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
JP2018507249A5 (2)
NZ602385A (en) Methods of treating cancer
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2018005071A (es) Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
MX370662B (es) Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
PH12015502046B1 (en) Pyridinyl and fused pyridinyl triazolone derivatives
JP2015536950A5 (2)
PH12016502354A1 (en) Pharmaceutical composition
MX2017015936A (es) Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos.
JP2017528475A5 (2)
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
EP4647126A3 (en) Stabilizing camptothecin pharmaceutical compositions
WO2013112950A3 (en) Certain chemical entities, compositions, and methods
GB2538683A8 (en) Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof
JP2017527582A5 (2)
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
JP2015502926A5 (2)